Alzheimer's Disease and Therapeutic Antibodies

<p>Bevacizumab (A)</p> Signup and view all the answers

<p>Over six times more savings (D)</p> Signup and view all the answers

<p>$558 m (B)</p> Signup and view all the answers

<p>Polyclonal antibodies are derived from a single cell line. (C)</p> Signup and view all the answers

<p>$406 m (B)</p> Signup and view all the answers

<p>Neuronal cell death (B)</p> Signup and view all the answers

<p>To cleave APP into non-toxic fragments (B)</p> Signup and view all the answers

<p>Degrading mRNA of APP (A)</p> Signup and view all the answers

<p>They lead to protein aggregation and toxicity (C)</p> Signup and view all the answers

<p>Preventing aggregation and enhancing removal of A-beta (C)</p> Signup and view all the answers

<p>It correlates with the presence of neurodegenerative diseases (C)</p> Signup and view all the answers

<p>It requires precise genetic manipulation across the brain (A)</p> Signup and view all the answers

<p>Gamma secretase (B)</p> Signup and view all the answers

<p>Lecanemab (C)</p> Signup and view all the answers

<p>Biosimilars are made from living cells and may vary in structure. (B)</p> Signup and view all the answers

<p>Filgrastim (A)</p> Signup and view all the answers

<p>39 (D)</p> Signup and view all the answers

<p>Gantenerumab (B)</p> Signup and view all the answers

<p>Save around 50% in total market spending. (A)</p> Signup and view all the answers

<p>They must demonstrate no clinically meaningful differences in safety and efficacy. (A)</p> Signup and view all the answers

<p>Retacrit (A)</p> Signup and view all the answers

<p>Biosimilars may have different manufacturing processes. (C)</p> Signup and view all the answers

<p>Mylan (A)</p> Signup and view all the answers

<p>Maintaining the exact same attributes as the reference biologic. (C)</p> Signup and view all the answers

<p>Lecanemab and Aducanumab (A)</p> Signup and view all the answers

<p>Patents of originators expiring. (B)</p> Signup and view all the answers

<p>Boost competition and lower prices. (D)</p> Signup and view all the answers

A protein expressed in neurons; role is unclear.

An enzyme that cleaves APP, producing non-toxic fragments.

Toxic fragments produced when APP is mutated and cleaved abnormally.

Clumping of mis-folded or disordered proteins, often linked to diseases.

Mis-folded protein aggregates in the brain associated with Alzheimer's.

Loss of nerve cells due to toxicity from A-beta and plaques.

A method to degrade mRNA and decrease production of APP.

Antibodies designed to bind to A-beta and enhance its removal from the brain.

Biological products highly similar to an already approved reference product.

Savings expected after the introduction of biosimilars, significantly reducing costs.

Antibodies made by identical immune cells that are clones of a unique parent cell.

Antibodies produced by different plasma cell lineages, targeting multiple antigens.

Composed of variable and constant regions, forming Y-shaped molecules.

Biosimilars increase competition, leading to lower prices and greater access.

Administering a vaccine to induce immunity against diseases.

A promising therapeutic antibody for Alzheimer's, approved in 2023.

Generics are identical to small molecule drugs; biosimilars are not identical to biologics.

Manufacturers must show no clinically meaningful differences from the original biologic.

The first US biosimilar was approved in 2015.

As of 2022, 39 biosimilars were approved in the US.

Biosimilars typically arrive about 20 years after the original product's market launch.

Biosimilars are expected to reduce total market spending by about 50%.

Brand name for Lecanemab is Legembi.

Some biosimilars like Donenemab and Trontinemab are still in trials as of 2023.

Generics have the exact same molecular structure as brand-name drugs.

Drugs derived from living cells used in treatment.

A cell line used to produce monoclonal antibodies.